19 Results for "

C5b

" in MedChemExpress (MCE) Product Catalog:
Products (19)

19 Results for "C5b" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-P7695
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rMuC5a; Complement C5; Hemolytic Complement; C5a
Species:  
Source:  
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P9914
CAS No.: 219685-50-4
Synonyms: Anti-Human C5, Humanized Antibody; h5G1.1
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-128342
CAS No.: 2365402-67-9
Purity:  99.14%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Compound C5-IN-1 (Compound 7) is a selective allosteric inhibitor of complement component protein C5. Compound C5-IN-1 prevents C5 from being cleaved by C5 convertase, inhibits the cleavage of C5 into C5a and C5b, and thus blocks the formation of membrane attack complex (MAC). Compound C5-IN-1 has an IC50 of 0.77 μM and 5 nM in 50% human whole blood and 2% human serum to block MAC deposition induced by zymosan, respectively. Compound C5-IN-1 can be used to study diseases related to complement overactivation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700862
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P81185
Synonyms: C5; C6; C7; C8; C9; Complement component 5; Complement component 6; Complement component 7; Complement component 8; Complement component 9; MAC; Membrane attack complex; TCC; Terminal complement complex.

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, ICC/IF

Reactivity:  

Human, Rat

loading...
    loading...
Cat. No.: HY-147080
CAS No.: 1491144-00-3
Purity:  98.53%
Synonyms: ARC1905
Target:  

Complement System

Research Areas:  

Others

Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system .
loading...
    loading...
Cat. No.: HY-P99965
CAS No.: 1917321-26-6
Synonyms: SKY59; RO7112689; RG-6107
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
loading...
    loading...
Cat. No.: HY-148457
CAS No.: 1613641-69-2
Synonyms: Izervay
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .
loading...
    loading...
Cat. No.: HY-P99638
CAS No.: 2456407-94-4
Synonyms: ALXN-1720

Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P990753
CAS No.: 2763342-87-4
Synonyms: CAN-106

Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Omoprubart is an anti-C5 complement recombinant humanized monoclonal antibody. Omolubat can prevent C5 from cleaving into C5a and C5b, thereby inhibiting the formation and activation of the C5b-dependent membrane attack complex (MAC) on the surface of susceptible cells, leading to cell lysis (destruction). Omoprubart can be used for the study of paroxysmal nocturnal hemoglobinuria (PNH).
loading...
    loading...
Cat. No.: HY-P990955
CAS No.: 2839652-75-2
Synonyms: ADX-097

Target:  

CD3 Complement System

Research Areas:  

Inflammation/Immunology

Ebribafusp alfa (ADX-097) comprising a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of factor H (fH1-5). Ebribafusp alfa binds C3d and related fragments, catalyzes AP convertase dissociation, acts as a factor I co-factor for C3b cleavage, and delivers fH1-5 moieties to C3d-deposited tissues for local complement inhibition without systemic blockade. Ebribafusp alfa reduces glomerular C3 deposition, proteinuria, urine albumin-creatinine ratios, and urine soluble C5b-9 levels, preserves podocyte foot-process architecture, inhibits skin complement activation, and localizes to UVB-damaged primate skin. Ebribafusp alfa can be used for the research of membranous nephropathy, bullous pemphigoid, discoid lupus erythematosus, C3 glomerulopathy, IgA nephropathy, and lupus nephritis .
loading...
    loading...
Cat. No.: HY-P704336
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P704546
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P704547
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-RS01749
Research Areas:  

Others

C5 Human Pre-designed siRNA Set A contains three designed siRNAs for C5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P88027

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, IF-Tissue, IP

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P7695A
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rMuC5a; Complement C5; Hemolytic Complement; C5a
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P77540
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Complement C5; Hemolytic Complement; C5a
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P705283
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Complement C5; Hemolytic Complement; C5a
Species:  
Rat
Source:  
loading...
    loading...
  • 1